Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19264355 | 0.89 | CSF1R (0.37) | CSF1R | |
| SCHEMBL3715632 | 0.87 | CSF1R (0.38) | CSF1RTBK1 | |
| SCHEMBL25210432 | 0.82 | CSF1R (0.38) | CSF1R | |
| SCHEMBL19264601 | 0.81 | CSF1R (0.35) | CSF1R | |
| SCHEMBL3913109 | 0.80 | CSF1R (0.40) | CSF1RTBK1 | |
| SCHEMBL1858413 | 0.79 | CSF1R (0.55) | CSF1RTBK1 | |
| SCHEMBL3165602 | 0.78 | HTR2C (0.40) | CSF1R | |
| SCHEMBL13884096 | 0.77 | CSF1R (0.53) | CSF1R | |
| SCHEMBL1858901 | 0.77 | CSF1R (0.56) | CSF1RTBK1 | |
| SCHEMBL4234422 | 0.77 | CSF1R (0.35) | CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3208269-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-15 | — | — | EP | disclosed |
| EP-3208269-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica N.V. (BE) | 2017-08-23 | — | — | EP | disclosed |
| EP-2215079-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-14 | — | — | EP | disclosed |
| US-8497376-B2 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-30 | — | — | US | disclosed |
| US-8497376-B2 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-30 | — | — | US | disclosed |
| US-8497376-B2 | 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-07-30 | — | — | US | disclosed |
| US-20090105296-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105296-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105296-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| WO-2009052237-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105296-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CSF1R 59/4885TBK1 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.